Latest Commercialization News

Cann Group Limited has reported a strong operational update, exceeding its medicinal cannabis production targets and significantly reducing costs, while expanding sales channels and securing fresh capital to bolster its balance sheet.

F.F.I. Holdings Ltd anticipates a substantial uplift in its property valuations as of June 2025, driven by rising asset values in both investment and own-use properties.

Cavalier Resources has cleared a key technical hurdle with Raptor Capital completing due diligence on the Crawford Gold Project, paving the way for binding $11 million stream finance negotiations. The updated Pre-Feasibility Study reinforces the project's strong economic potential.

Nanollose Limited has appointed Andrew Moullin as its new CEO and Managing Director, aiming to leverage his extensive commercial expertise to fast-track the company’s microbial cellulose technology towards market readiness.

Dimerix has activated the first clinical trial site in Japan for its pivotal Phase 3 ACTION3 study targeting FSGS, triggering a significant milestone payment from its Japanese partner FUSO Pharmaceutical.

Nanoveu’s subsidiary EMASS has hit a key milestone with its ECS-DoT chip achieving 50 updates per second in drone flight simulations, enabling smarter, more stable drones with up to 30% longer flight times.

RareX Limited has partnered with Gega Elements to develop Australia’s inaugural integrated gallium supply chain, aiming to reduce reliance on Chinese supply and boost national critical mineral resilience.

Rumble Resources updates its Western Queen Gold Project with a revised open pit mine plan that increases capital needs, explores underground mining, and eyes a new tungsten revenue stream.

The Arkansas Oil & Gas Commission has approved a 2.5% lithium royalty for brine projects, providing Pantera Lithium with regulatory clarity and a competitive fiscal framework that enhances its Smackover Project’s commercial prospects.

Pacific Edge Limited has launched a NZ$20 million capital raise to bolster its cash reserves amid the loss of Medicare coverage for its bladder cancer diagnostic tests, aiming to accelerate US market adoption and support new product development.

Pacific Edge Limited reported a resilient FY25 performance despite losing Medicare coverage for its Cxbladder tests in the US, announcing a $20 million equity raise to support commercialization and growth.

Rare Foods Australia Limited has requested an immediate suspension of its shares on the ASX, paving the way for its voluntary removal from the exchange next month. This move follows shareholder approval earlier this year.